Locations:
Search IconSearch
January 25, 2018/Neurosciences/Research

Comprehensive Vs. Primary Stroke Centers: Is There a Quality Difference?

CSCs achieve timelier acute reperfusion therapy, national study finds

Streamlined STEMI Protocol Slashes Door-to-Balloon Times

Do Comprehensive Stroke Centers really offer an advantage over Primary Stroke Centers in providing patient care?

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

According to a large new national study of stroke centers, the answer is yes, at least on a few key measures, although overall stroke care was found to be broadly similar between the two certification levels. The study was presented at the 2018 International Stroke Conference in Los Angeles. (Editor’s note: The full study was published online by Circulation: Cardiovascular Quality and Outcomes on May 23, 2018.)

“Determining whether Comprehensive Stroke Centers offer an advantage and, if so, how much of one, is important for allocating resources to optimize patient care,” says Ken Uchino, MD, Director of Research and Education for Cleveland Clinic’s Cerebrovascular Center and a co-author of the multicenter study. “Does every community need a Comprehensive Stroke Center? Does every patient with an acute stroke need to be referred to one? Such questions are worth investigating.”

The certifications at a glance

To briefly define terms, The Joint Commission provides certification to hospitals that meet standards recommended by the Brain Attack Coalition for care of acute stroke. Since 2012, two levels of certification have been offered: Primary Stroke Centers (PSCs) and Comprehensive Stroke Centers (CSCs), with the latter designation requiring an ability to provide more-complex services, including 24/7 availability of endovascular procedures.

Study design

Investigators with the current study used the American Heart Association/American Stroke Association’s Get With The Guidelines®–Stroke database to identify consecutive patients with a final diagnosis of acute ischemic stroke who were admitted to 134 CSCs (110,624 patients) and 1,047 PSCs (494,512 patients) between January 1, 2013, and December 31, 2015.

Advertisement

Multivariable regression analysis was done to explore associations between facilities’ certification level and performance measures and outcomes, after adjustment for potential confounding variables.

Key findings

CSCs were noted to be larger than PSCs, with median bed counts of 481 versus 263, respectively.

Almost all hospitals in both groups (94 percent) were found to conform with seven key performance measures, including intravenous thrombolysis among those arriving within two hours of symptom onset; use of antithrombotic medication and deep vein thrombosis prophylaxis in appropriate patients; discharge medications for atrial fibrillation and lipid lowering when indicated; and addressing smoking cessation.

However, CSCs outperformed PSCs in several key measures, especially in the use of intravenous tissue plasminogen activator (IV tPA) and intra-arterial thrombectomy (IA therapy). Among the significant differences:

  • IV tPA was administered to 14.3 percent of patients in CSCs versus 10.3 percent in PSCs (adjusted odds ratio [OR] = 1.23; 95% CI, 1.12-1.34).
  • Time from door to delivery of IV tPA was within one hour in 79.7 percent of patients in CSCs versus 65.1 percent in PSCs (adjusted OR = 1.48; 95% CI, 1.25-1.75).
  • Median time from door to IV tPA was 52 minutes in CSCs versus 61 minutes in PSCs (adjusted OR = 0.92; 95% CI, 0.89-0.95).
  • IA therapy was provided in 4.1 percent of patients in CSCs versus 1.0 percent in PSCs (adjusted OR = 2.35; 95% CI, 1.82-3.04).
  • Median time from door to IA therapy was 145 minutes in CSCs versus 152 minutes in PSCs (adjusted OR = 0.92; 95% CI, 0.87-0.98).

Advertisement

“We observed that CSCs are slightly but significantly better at providing prompt acute treatment,” says Dr. Uchino. “But overall, stroke care is similar between CSCs and PSCs, and both types of facilities are achieving good quality process measures.”

Data hide nuances

Dr. Uchino notes that there are many complexities in doing a study such as this one. Some PSCs are actually equivalent to CSCs but for various reasons have not pursued the higher certification. Others may provide thrombectomy (one of the key differences between the certification levels) but are missing other elements believed to be less critical. Such issues potentially confound the data by blurring differences between the two types of facilities.

Interestingly, the study found that in-hospital mortality was modestly higher at CSCs than at PSCs, even after adjusting for patient comorbidities (4.6 percent versus 3.8 percent; adjusted OR = 1.14; 95% CI, 1.01-1.29). According to Dr. Uchino, the current study cannot account for this difference, and he suspects other unmeasured variables may offer an explanation since it’s unlikely that the higher level of care measures at CSCs found in the study led to more deaths.

“It is critical for facilities to be transparent about their outcomes by collecting data on their performance measures and making them available for investigation and comparison,” he adds. “This is the only way we can determine if initiatives such as acute stroke care certification are important and how to further improve patient outcomes.”

Advertisement

Cleveland Clinic’s main campus hospital is a Joint Commission-certified Comprehensive Stroke Center. Cleveland Clinic health system also includes seven Primary Stroke Centers.

Advertisement

Related Articles

Two-dimensional scatter plot of peak T1 versus T2 times from pre-extended lumbar drainage MRI

MR Fingerprinting Predicts Shunt Efficacy in NPH

Study tests potential for a more accurate treatment predictor

person going into a Gamma Knife machine for radiotherapy
March 25, 2026/Neurosciences/Brain Tumor

Predicting Response to Stereotactic Radiosurgery for Recurrent Glioblastoma

Study uses molecular and clinical stratification to help guide patient selection

illustration of human brain with rumor at top right
March 23, 2026/Neurosciences/Brain Tumor

Adding Eflornithine to Lomustine Extends Survival in Recurrent IDH-Mutant Grade 3 Astrocytoma

Phase 3 STELLAR trial underscores role of molecular stratification in glioma care

brain MRI taken from the back of the head
March 20, 2026/Neurosciences/Epilepsy

Unmasking the ‘Tethered’ Temporal Lobe: New MRI Metrics Improve Detection of Encephaloceles in Refractory Epilepsy

Early identification of temporal encephaloceles can improve surgical decision-making

brain scan with white lesion on right side

ARISE II Recommendations Chart a Course for Advancing Intracranial Hemorrhage Care

Academia, industry and government leaders develop consensus priorities

two brain scans side by side with a yellow circle on the left scan
March 13, 2026/Neurosciences/Epilepsy

SEEG Linked With More Complete Resection and Greater Seizure Freedom in MOGHE Subtype of Epilepsy

Insights from one of the first studies of invasive monitoring in the rare form of focal cortical dysplasia

histopathology image with pink background and arrow pointing to round cell

New Insights on α-Synuclein Pathology and Clinical Phenotypes in Dementia With Lewy Bodies

The disease’s neuropathologic heterogeneity holds clues to refining diagnosis and prognosis

MRI of the brain against black background

Advanced Neuroimaging and Clinical Perseverance Make Sense of a 68-Year-Old’s Progressive Symptoms

A case study in pairing imaging acumen with subspecialty expertise to yield answers and symptom relief

Ad